A Phase 2, Multicenter, Open-label, Safety and Efficacy Study of XERMELO (Telotristat Ethyl) Plus First-line Chemotherapy in Patients With Locally Advanced, Unresectable, Recurrent or Metastatic Biliary Tract Cancer (BTC)
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Feb 2019
At a glance
- Drugs Telotristat etiprate (Primary)
- Indications Biliary cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Lexicon Pharmaceuticals
- 06 Feb 2019 Planned initiation date changed from 1 Jan 2019 to 1 Feb 2019.
- 27 Dec 2018 Status changed from planning to not yet recruiting.
- 01 Nov 2018 According to the Lexicon Pharmaceuticals media release, the company expects to initiate this trial in Q4 2018.